VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25092940.
- Also identified by DOI 10.1542/peds.2013-2272.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This report describes an 8-year-old child with acute anthracycline-induced cardiomyopathy triggered by human herpesvirus 6 and the subsequent implantation of an intracorporeal continuous-flow left ventricular assist device (LVAD) and the process to discharge the child from the hospital. After barely 3 months on mechanical support, the device was explanted after thorough examination. Experiences regarding LVAD removal are limited, and no guidelines for echocardiographic and hemodynamic criteria for LVAD removal in children have been published thus far. We present our institutional algorithm for device selection, surveillance in an ambulatory setting, and testing for myocardial recovery, as well as our criteria for LVAD explantation in children.
Medical subject headings
- Anthracyclines
- Heart-Assist Devices
- Herpesvirus 6, Human
- Myocarditis
- Roseolovirus Infections